I take 5 g of creatine monohydrate daily and my egfr has not fallen much. It’s at 108. Cystatin C is 0.85. Both are great.
I also take 12.5 mg of empagliflozin daily as I want to keep my kidneys in great shape going forward.
Many people think about taking a flozin when their kidneys are in trouble. That’s like not changing the oil in your car until you hear clunking noises from the engine.
I’m taking empagliflozin proactively to keep my kidneys in top condition. It’s like changing the oil every 3 months. It may be a little too much, but I’m not going to freeze up my engine.
How is the pricing on quest? I’m moderately satisfied with labcorps, because in my area they seem to have more tests, and they are cheaper. I also use fitomics, which has just started adding more tests to choose from.
You’re right David…I am doing 10 mg creatine. 5 mg morning… 5 mg more end of day before gym workout.
Doing weekly 200 mg 1 ml cypionate too.
My Hematocrit is good- last blood test 48.2 high normal. I will keep an eye on it now that I am using an SGLT2 inhibitor.
I’m doing Fitomics as well. I haven’t really gone and compared the prices between Quest and LabCorp directly, but either way I’m sticking w/Quest due to the factors I mentioned above.
Really not sure what makes Henagliflozin special. From what I can see it’s a typical “me too” drug, but of course, I might have missed something. Approved in China and not many other places doesn’t make me enthusiastic unless there’s some independent studies outside of China. But it seems fairly new, so probably not many studies. Not sure why we should be excited over it, but hey, the more the merrier, options are always good.
We identified GLP-1 receptor agonist initiation compared to DPP-4 inhibitors initiation was associated with a reduced risk of AD (hazard ratio [HR] ≤ 0.69 and P value < 0.001) and SGLT-2 inhibitor initiation compared to DPP-4 inhibitor initiation was associated with a reduced risk of AD (HR ≤ 0.67 and P value < 0.001).
Two GLP-1 receptor agonists (liraglutide and semaglutide) and three SGLT-2 inhibitors (dapagliflozin, canagliflozin, and empagliflozin) are associated with a reduced risk of AD in drug-specific sensitivity analyses.
I’ve switched all my blood work from LabCorp to Quest. At least in my area, the difference in service is night and day better w/Quest. LabCorp is overbooked, understaffed, and getting my results is like pulling teeth. Quest automatically releases each test result as it comes in, whereas LabCorp waits until ALL results have come in before releasing anything unless you go to their website and request special permission EVERY TIME to get “preliminary results”.
I recently used Quest (through Ulta) for the first time and that was my experience as well. Ulta also offers a greater variety of tests and at better prices compared to Marek
Semaglutide is looking good, but what the heck is going on with ertugliflozin, some kind of artifact(?) - wide CI bars.
And from the paper:
“The effects of GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors in AD and PD remain inconclusive in subgroups.”
What subgroups are they talking about wrt. PD?
Also looking at Fig. 3A, in “under or normal weight” SGLT2 was not protective for AD (in contrast to 3B), though wide CI bars, maybe the difference between 3A and 3B is the inclusion of “under” in 3A (Clinformatics).
Let’s keep in mind, these were older cohorts, understandably for AD (prevalence), but a pity no younger cohorts for PD. Also generally disappointing for PD.
Subgroups are for AD and PD. I assume they meant “obese”, “diabetic”, “young”, “old”, etc.
3.4 Other results
For PD, no consistent differences were observed in all comparisons (GLP-1 receptor agonist vs. DPP-4 inhibitors, SGLT-2 inhibitors vs. DPP-4 inhibitors, and GLP-1 receptor agonists vs. SGLT-2 inhibitors; Figures S12–S15 in supporting information). Full results of Cox models in overall analyses of Clinformatics data are presented in Tables S5–S7 in supporting information.
